[Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto
Noriko
N
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine.
Tajima
Naoko
N
D020909:Acarbose / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D050260:Carbohydrate Metabolism; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018149:Glucose Intolerance / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance; D007408:Intestinal Absorption / Q000187:drug effects; D019518:Postprandial Period; D011322:Primary Prevention
D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D020909:Acarbose